Actos Attorneys Resources
Actos Attorneys: The exact mechanism(s) of BCG is still not fully understood. It is known BCG actually attaches to and enters cancer cells. BCG is thought to trigger an increased immune reaction in the bladder, thereby killing off cancer cells. BCG is held in the bladder for two hours. One should not hold it longer as adverse reactions are increased. The individual should then void into a toilet at home, preferably in a seated position to avoid splashing. After voiding, the toilet is disinfected with bleach. Since BCG can be shed from the urethra after treatment for several days, condoms should be used or one should abstain from sexual relations for at least 48 hours after treatment.
Studies have shown an approximately 40% reduction in tumor recurrence in those treated with BCG as compared with those without treatment.For those with CIS, the reduction is even greater at approximately 70%. For individuals with residual tumors after resection, complete response is generally about 60%.Despite intravesical therapy, ultimately between 10-20% of individuals with superficial bladder cancer will develop muscle invasive disease.
After a 6 week induction course of weekly BCG, treatment is often repeated with 3 weekly treatments at 3 months, 6 months and then every 6 months for up to 3 years. This regimen was shown to decrease recurrences and increase complete responses as compared to induction treatment alone. Unfortunately, despite initial success, over long periods of time, many will experience disease recurrence and progression.Treatment regimens can be individualized based on the patient’s progress and his adverse reactions to treatment, which generally increase with repeated cycles.
For more information on Actos Attorneys follow us on our RSS Feeds.
Adverse reactions are side effects of treatment. Approximately 95% of individuals will tolerate treatments well. Adverse reactions may be mild. Common reactions include cystitis (inflammation of the bladder characterized by burning on urination), hematuria, mild fever, malaise, and nausea. These symptoms generally pass without any treatment. For bothersome symptoms, various medications may prove helpful. Your physician can prescribe medication for burning or urinary frequency. For those with persistent cystitis, antibiotics can be utilized. For individuals experiencing severe symptoms lasting more than 48 hours, isoniazid, an anti-tuberculous drug can be prescribed. A short course of 3 days, starting the day before the next dose of BCG can be used to prevent severe side effects. Fortunately severe reactions resulting in sepsis, a life threatening condition characterized by high fever, chills and drop in blood pressure, is exceedingly rare. Sepsis would be treated in a hospital with triple anti-tuberculous drugs, steroids, and broad spectrum antibiotics.
Information from other sources on Actos Attorneys
As treatment cycles progress, generally adverse reactions increase in severity, the most common being cystitis. Patients should not receive additional doses until they are asymptomatic. Studies have demonstrated increasing the intervals between treatments and reducing the dose of the BCG can still result in perhaps equal efficacy, but with reduced toxicity. BCG therapy results in marked inflammation of the bladder wall. Cystoscopy done too soon after therapy would reveal a markedly reddened surface, making finding a bladder tumor difficult. Furthermore, microscopically, there will be severe reactive changes, complicating the pathologist’s job, as deciding between changes from the BCG and recurrent cancer, would be extremely difficult.
Recurrence of bladder cancer after the initial induction course, or relapse after complete response, would indicate failure of therapy. When two or more courses result in recurrence or when recurrence develops during the first six to twelve months after induction and maintenance therapy, patients generally are felt to have disease which is at higher risk for progression. A high percentage of patients who are complete responders remain tumor free for up to five years. However, with the passage of more time, additional patients will have late recurrences. For those with late recurrences (two to three years after therapy), most will respond to repeat BCG therapy.
Our use of the term or terms Actos Attorneys is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.
To keep up to date on Actos Attorneys visit our site often.
Actos Attorneys